ACA
MRKR icon

Apis Capital Advisors’s Marker Therapeutics MRKR Stock Holding History

Apis Capital Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-9,000
Closed -$713K – 31
2019
Q2 		$713K Buy
+9,000
New +$535K 1.07% 23

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Apis Capital Advisors's MRKR Position: Q3 2019 in Review

Apis Capital Advisors sold out of Marker Therapeutics (MRKR) in Q3 2019, closing a stake of 9,000 shares — an estimated $713K sold.

Apis Capital Advisors first reported a position in MRKR in Q2 2019 and held it in 1 quarter. The position peaked at $713K in Q2 2019. 73 funds tracked by Wall St. Rank hold MRKR as of Q3 2019.

  • Apis Capital Advisors reported no remaining Marker Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Apis Capital Advisors sold 9,000 Marker Therapeutics shares in Q3 2019, an estimated $713K.
  • Apis Capital Advisors first reported a position in Marker Therapeutics in Q2 2019 and held it in 1 quarter.
  • Apis Capital Advisors's Marker Therapeutics position peaked at $713K in Q2 2019.
  • 73 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2019.

Based on Apis Capital Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.